Immunome to Present at 13th Annual World ADC London Conference
Immunome, Inc. (IMNM)
Company Research
Source: Business Wire
EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop antibody therapeutics to improve patient care, today announced that Matthew Robinson, Ph.D., Chief Technology Officer, will present at the 13th Annual World ADC London conference, taking place from March 13-16, 2023.World ADC London is Europe’s longest standing and definitive antibody-drug conjugate (ADC) event dedicated to maximizing the therapeutic window of ADCs. Dr. Robinson will give a platform talk on Wednesday, March 15 discussing how Immunome’s Discovery Engine can highlight novel target classes which have relevance for multiple therapeutic modalities, including ADCs. Full presentation details are included below.“Human memory B cells are able to record the targets that are classified as important attack points for antibodies across the course of tumor development. With our proprietary Discovery Engine, we can harness
Show less
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Immunome, Inc. (NASDAQ: IMNM) is now covered by analysts at Guggenheim. They set a "buy" rating and a $35.00 price target on the stock.MarketBeat
- Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling [Seeking Alpha]Seeking Alpha
- Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual MeetingBusiness Wire
- Immunome, Inc. (NASDAQ: IMNM) had its price target raised by analysts at Wedbush from $27.00 to $33.00. They now have an "outperform" rating on the stock.MarketBeat
IMNM
Sec Filings
- 4/3/24 - Form S-3ASR
- 4/3/24 - Form S-3ASR
- 3/28/24 - Form 10-K
- IMNM's page on the SEC website